A new study shows Signatera ctDNA testing may identify older patients with ER+/HER2- breast cancer who can manage their care ...

Natera Inc. NTRA shares are up on Tuesday as the company announced promising results from a prospective study regarding its ...

The firm validated its test for one new indication in 64 patients with a variety of solid tumors, including breast, ovarian, melanoma, and head and neck cancers.

India - Delhi High Court Dismisses Appeal Against Refusal Of Smelling Disease Patent. Legal News and Analysis - India - ...

For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, ...

PITTSBURGH - For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, in part ...

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.

Natera launches Zenith genomics whole-genome sequencing assay with MyOme to boost rare disease detection and expand ...

Initial 2026 guidance calls for revenue of $2.62 billion to $2.70 billion, implying around 25% growth over 2025 when backing out true-ups. Natera is targeting gross margins of 63% to 65% while holding ...

Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter for the “Carillon Eagle Mid Cap Growth Fund”. A copy of the letter can be downloaded here.

In the last week, the United States market has stayed flat but is up 16% over the past year, with earnings forecasted to grow ...